clinical trial · NCT06997081
ERd Combination Treatment in Newly Diagnosed Multiple Myeloma
University of Miami·phase2·recruiting·n = 104
Multiple MyelomaLenalidomideDexamethasoneElranatamab
brief summary
The purpose of this study is to determine the effects that Elranatamab in combination with Lenalidomide and Dexamethasone has on participants that have been newly diagnosed with Multiple Myeloma.
started
Sep 16, 2025
primary completion
Sep 30, 2030
completion
Sep 30, 2030
last updated
Oct 7, 2025
official title
Elranatamab, Lenalidomide, Dexamethasone in Newly Diagnosed Multiple Myeloma, a Clinical and Correlative Phase 2 Study
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol